Hints and tips:
...And it plans to acquire oncology-focused biotech Seagen for $43bn, which it expects to contribute more than $10bn in 2030 sales....
...specialists....
...S&P 500 stock....
...In Canada total transactions jumped to C$87bn ($64bn) last year, according to Bloomberg, up nearly nine times since 2021. US banks are just getting going, and in size....
...to c.$1.2bn....
...In contrast, the multi-manager model relies on specialist traders, overseen by sophisticated risk management technology, and a ruthless approach to hiring and firing by their paymasters....
...Higher risks make this a market for specialists. The perimeter of the financial junkyard is defined by a rating of BB+ from Fitch and S&P, and Ba1 from Moody’s....
...After assembling a team of specialists for a complicated job, a contractor falls asleep on a plane....
...ETFs struggle, however, to compete with trusts in more specialist corners of the investment universe....
...Business coach Julie Stokes has just helped launch a new executive retreat at Goodwood with gut-health specialist and psychotherapist Stephanie Moore....
...Citadel, which suffered badly in the 2008 financial crisis but has gone on to post returns well ahead of the S&P 500 and its peers, was last year able to put on risk when many other investors were running...
...Just $3bn of risky triple-C rated US bonds and loans have been issued into the broad market this year, down 78 per cent from last year, according to data from PitchBook LCD and Refinitiv....
...Non-specialist investors and hedge funds piled in, pushing up valuations and funding large swaths of start-ups that had not even begun human trials....
...A total of 51 large retailers filed for bankruptcy in the US in 2020 — a decade high, according to S&P Global Market Intelligence....
...Specialist indices also rank highly in terms of assets under management, according to ETFGI, including the S&P Global Clean Energy Index and the MAC Global Solar Energy Index....
...Gilead Sciences has spent years and billions of dollars developing its oncology business....
...For Gilead this would be the third blockbuster oncology-focused deal in three years....
...of the S&P 500....
...If the bondholders call in their debt, M&B could sell some of its 1,356 securitised pubs (last valued at c£4bn) to pay off c£1.7bn of notes and c£0.3bn of MTM swaps....
...Here’s Goldman: Varian is the market leader in the global radiation oncology market, with c.60% market share, with Elekta the other sizeable player, at c.40% market share....
...Best known for its HIV treatments and its medications for hepatitis C, Gilead has come under pressure following a drop in sales for some of its blockbuster drugs and a legal fight with the US government...
...Nordics P&C exposure through If P&C and Topdanmark supports around 60% of Sampo’s dividend, where this is expected to remain stable....
...The company’s valuation stands at a rather mind-boggling 29 times forward revenues, according to S&P Global data, and it’s share price is up a staggering 236 per cent this year....
...P&G, the world’s largest consumer goods company, bought the vitamins and supplements business of pharmaceutical group Merck for $4.2bn in 2018....
...Stifel likes: The company has agreed to pay a cash consideration of $130m on a cash and debt-free basis, which equates to c.2.9x 2019 revenues and c.9.7x EBITDA 2019 EBITDA....
International Edition